Literature DB >> 35373076

Late Relapses of Membranous Nephropathy: A Case Series.

Yonatan Peleg1, Andrew S Bomback1, Pietro A Canetta1, Jai Radhakrishnan1, Gerald B Appel1, Wooin Ahn1.   

Abstract

Background: Relapse of the nephrotic syndrome is co mmon among patients with primary membranous nephropathy (MN). Relapses of MN typically occur within a few years of achieving disease remission. There is limited description, to date, regarding patients with MN who have late relapse of MN, i.e., after >5 years of sustained disease remission. The objective of this case series was to report the clinical course of patients with MN who experience late relapse.
Methods: We analyzed the patient database of the Glomerular Kidney Disease Center at Columbia University to identify patients seen at our center who had relapse of biopsy specimen-proven MN at least 5 years after achieving sustained disease remission.
Results: We identified 16 patients with late relapse of MN. The median time in sustained remission before relapse was 10.2 (range, 7-29.0) years. Ten patients (63%) were diagnosed with late relapse on the basis of laboratory monitoring alone, without clinical symptoms of the nephrotic syndrome. Fourteen patients (88%) received immunosuppression during their initial presentation and late relapse. Patients had favorable long-term renal outcomes over a median 21 (range, 12-56) year follow-up period, with 14 patients (88%) in remission at study conclusion and a median decline in eGFR per year of -0.63 (range, -6.3 to 17.5) ml/min per 1.73 m2 per year. Conclusions: This case series highlights a previously underappreciated, and likely rare, outcome of MN, namely, late relapse. Patients who experience late relapse, and who thus have a longer time in sustained remission, may have a more favorable long-term renal outcome.
Copyright © 2021 by the American Society of Nephrology.

Entities:  

Keywords:  glomerular and tubulointerstitial diseases; late relapse; membranous nephropathy; natural history; nephrotic syndrome; proteinuria; relapse

Mesh:

Year:  2021        PMID: 35373076      PMCID: PMC8791370          DOI: 10.34067/KID.0007712020

Source DB:  PubMed          Journal:  Kidney360        ISSN: 2641-7650


  21 in total

1.  Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.

Authors:  Fernando C Fervenza; Gerald B Appel; Sean J Barbour; Brad H Rovin; Richard A Lafayette; Nabeel Aslam; Jonathan A Jefferson; Patrick E Gipson; Dana V Rizk; John R Sedor; James F Simon; Ellen T McCarthy; Paul Brenchley; Sanjeev Sethi; Carmen Avila-Casado; Heather Beanlands; John C Lieske; David Philibert; Tingting Li; Lesley F Thomas; Dolly F Green; Luis A Juncos; Lada Beara-Lasic; Samuel S Blumenthal; Amy N Sussman; Stephen B Erickson; Michelle Hladunewich; Pietro A Canetta; Lee A Hebert; Nelson Leung; Jay Radhakrishnan; Heather N Reich; Samir V Parikh; Debbie S Gipson; Dominic K Lee; Bruno R da Costa; Peter Jüni; Daniel C Cattran
Journal:  N Engl J Med       Date:  2019-07-04       Impact factor: 91.245

2.  Detection of PLA2R Autoantibodies before the Diagnosis of Membranous Nephropathy.

Authors:  Peter D Burbelo; Megha Joshi; Adrija Chaturvedi; Dustin J Little; John S Thurlow; Meryl Waldman; Stephen W Olson
Journal:  J Am Soc Nephrol       Date:  2019-12-16       Impact factor: 10.121

3.  MHC Class II Risk Alleles and Amino Acid Residues in Idiopathic Membranous Nephropathy.

Authors:  Zhao Cui; Li-Jun Xie; Fang-Jin Chen; Zhi-Yong Pei; Li-Jie Zhang; Zhen Qu; Jing Huang; Qiu-Hua Gu; Yi-Miao Zhang; Xin Wang; Fang Wang; Li-Qiang Meng; Gang Liu; Xu-Jie Zhou; Li Zhu; Ji-Cheng Lv; Fan Liu; Hong Zhang; Yun-Hua Liao; Lu-Hua Lai; Pierre Ronco; Ming-Hui Zhao
Journal:  J Am Soc Nephrol       Date:  2016-11-16       Impact factor: 10.121

4.  Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial.

Authors:  M Praga; V Barrio; G Fernández Juárez; J Luño
Journal:  Kidney Int       Date:  2007-03-21       Impact factor: 10.612

5.  The natural history of the non-nephrotic membranous nephropathy patient.

Authors:  Michelle A Hladunewich; Stephan Troyanov; Jennifer Calafati; Daniel C Cattran
Journal:  Clin J Am Soc Nephrol       Date:  2009-08-06       Impact factor: 8.237

6.  Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy.

Authors:  Horia C Stanescu; Mauricio Arcos-Burgos; Alan Medlar; Detlef Bockenhauer; Anna Kottgen; Liviu Dragomirescu; Catalin Voinescu; Naina Patel; Kerra Pearce; Mike Hubank; Henry A F Stephens; Valerie Laundy; Sandosh Padmanabhan; Anna Zawadzka; Julia M Hofstra; Marieke J H Coenen; Martin den Heijer; Lambertus A L M Kiemeney; Delphine Bacq-Daian; Benedicte Stengel; Stephen H Powis; Paul Brenchley; John Feehally; Andrew J Rees; Hanna Debiec; Jack F M Wetzels; Pierre Ronco; Peter W Mathieson; Robert Kleta
Journal:  N Engl J Med       Date:  2011-02-17       Impact factor: 91.245

7.  HLA-DRB1*15:01 and HLA-DRB3*02:02 in PLA2R-Related Membranous Nephropathy.

Authors:  Wei-Bo Le; Jing-Song Shi; Tao Zhang; Lei Liu; Hua-Zhang Qin; ShaoShan Liang; Yuan-Wei Zhang; Cun-Xia Zheng; Song Jiang; Wei-Song Qin; Hai-Tao Zhang; Zhi-Hong Liu
Journal:  J Am Soc Nephrol       Date:  2016-12-27       Impact factor: 10.121

8.  Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate.

Authors:  Peggy W G du Buf-Vereijken; Amanda J W Branten; Jack F M Wetzels
Journal:  Nephrol Dial Transplant       Date:  2004-02-19       Impact factor: 5.992

9.  A new equation to estimate glomerular filtration rate.

Authors:  Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391

10.  Membranous Glomerulonephritis With Crescents.

Authors:  Aikaterini Nikolopoulou; Isabel Huang-Doran; Stephen P McAdoo; Megan E Griffith; H Terence Cook; Charles D Pusey
Journal:  Kidney Int Rep       Date:  2019-08-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.